Latest Industry Insights
Industry Insight
Live Biotherapeutics ‒ A Novel Way To Treat Disease
The intricate and intertwined nature of the host‒microbiota connection has garnered increasing interest from the scientific community in recent years, due to its known role in the development and progression of various diseases. 4D pharma has leveraged growing knowledge in the field, by creating a novel class of medicines called live biotherapeutic products (LBPs).
Industry Insight
When We Become Leaders, How Do We Lead Science Towards Gender Equity?
Emulate's chief scientific officer, Dr. Lorna Ewart, talks about inspiring a new generation of women in STEM.
Industry Insight
The Bright Future of mRNA
Technology Networks interviewed Frank DeRosa, chief technology officer and head of research at the mRNA Center of Excellence, Sanofi, to discuss the “bright future” of mRNA platforms.
Industry Insight
Collaboration Aims To Transform the Manufacturing of Cell Therapies
Due to the complexity of the cell therapy products and patient-specific variability, product quality and consistency are significant challenges in manufacturing. In this exclusive interview, we learn more about these challenges and the ways they can be overcome.
Industry Insight
Moving Towards the Next Era in Rare Disease Therapeutics
In this two-part interview series, Technology Networks explores some of the reasons behind the difficulties diagnosing and treating rare diseases, and finds out more about recent developments to improve options for patients.
Industry Insight
Targeting EBV-Infected Cells To Treat Multiple Sclerosis
Technology Networks spoke to Atara’s chief medical officer, AJ Joshi, to learn more about ATA188 – an off-the-shelf, allogeneic T-cell immunotherapy – and how it could revolutionize treatment for MS patients.
Industry Insight
Can Precision Psychiatry Give Us New Ways To Treat Mental Health Disorders?
Our ability to treat disorders of the body has advanced significantly in the 21st century. But that progress has not been matched by new therapies for psychiatric conditions. atai Life Sciences, a clinical-stage biopharmaceutical company, recently launched a new company that aims to correct that imbalance.
Industry Insight
Leveraging the T-Cell Response to Epstein-Barr Virus To Treat Life-Threatening Diseases
Technology Networks recently spoke with Jakob Dupont, head of global research & development at Atara Bio, to learn more about the company’s novel allogeneic EBV T-cell platform and discover how it’s enabling a differentiated approach to allogeneic cell therapy.
Industry Insight
Women in Science: Perspectives From Industry
In honor of International Day of Women and Girls in Science 2022, Technology Networks interviewed three women who have built successful careers within the scientific industry, to learn about their career paths and the reasons they chose to work in industry.
Industry Insight
A One-Stop Platform To Drive Progress in Gene Therapy Development
In this interview, Dr. Ren discusses some of the challenges that currently exist when developing gene therapies and explores how Cyagen’s one-stop gene therapy platform can help to address them.
Advertisement